PT-141 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
=== Production and fermentation === First, raw milk (either from cattle, goats or sheep) is mixed and pasteurized at 72 °C (162 °F) for 15 seconds. Then, acidification occurs: a starter culture, such as Streptococcus lactis, is added in order to change lactose to lactic acid, thus changing the acidity of the milk and turning it from liquid to solid. The next step is coagulation, where rennet, a mixture of rennin and other materials found in the stomach lining of a calf is added to solidify the milk further. Following this, thick curds are cut typically with a knife to encourage the release of liquid or whey. The smaller the curds are cut, the thicker and harder the resulting cheese will become. After the curds have been ladled into containers in order to be drained and formed into a full wheel of cheese, the Penicillium roqueforti inoculum is sprinkled on top of the curds along with Brevibacterium linens. Then, the curd granules are knit in molds to form cheese loaves with a relatively open texture. Next, whey drainage continues for 10–48 hours in which no pressure is applied, but the molds are inverted frequently to promote this process. Salt is then added to provide flavor as well as to act as a preservative so the cheese does not spoil through the process of brine salting or dry salting for 24–48 hours. The final step is ripening the cheese by aging it. When the cheese is freshly made, there is little to no blue cheese flavor development. Usually, a fermentation period of 60–90 days is needed before the flavor of the cheese is typical and acceptable for marketing.
Maritime border control measures are controversial in the context of international trade disputes, as was the case following France's detention of British fishermen in October 2021 in the aftermath of Brexit or when the Indonesian navy detained the crew of the Seven Seas Conqueress alleging that the vessel was unlawfully fishing within Indonesian territorial waters while the Singaporean government claimed the vessel was in Singaporean waters near Pedra Branca. Similarly, international law accords each state control over the airspace above its land territory, internal waters, and territorial sea. Consequently, states have the authority to regulate flyover rights and tax foreign aircraft utilising their airspace. Additionally, the International Civil Aviation Organization designates states to administer international airspace, including airspace over waters that do not form part of any state's territorial sea. Aircraft unlawfully entering a country's airspace may be grounded, and their crews may be detained. No country has sovereignty over international waters, including the associated airspace. All states have the freedom to fish, navigate, overfly, lay cables and pipelines, and conduct research. Oceans, seas, and waters outside national jurisdiction are also referred to as the high seas or, in Latin, mare liberum (meaning free sea).
nuclease Any of a class of enzymes capable of cleaving phosphodiester bonds connecting adjacent nucleotides in a nucleic acid molecule (the opposite of a ligase). Nucleases may nick one strand or cut both strands of a duplex molecule, and may cleave randomly or at specific recognition sequences. They are ubiquitous and imperative for normal cellular function, and are also widely employed in laboratory techniques.
Phlebotonics of heterogeneous composition, consisting partly of citrus peel extracts (flavonoids, such as hesperidin) and synthetic compounds, are used to treat chronic venous insufficiency and hemorrhoids. Some are non-prescription dietary supplements, such as diosmin, while one other – Vasculera (Diosmiplex) – is a prescription medical food intended for treating venous disorders. Their mechanism of action is undefined, and clinical evidence of benefit for using phlebotonics to treat venous diseases is limited.
Sources: en.wikipedia.org
==== Anglo-American ==== Richard Steiff, the creator of the teddy bear, made the toy in 1902 under Margarete Steiff's felt goods company. The toys were brought to the US and gained mass popularity after a newspaper told the story of Theodore Roosevelt refusing to shoot a black bear cub tied to a tree. The fictional character Winnie-the-Pooh was named after Winnipeg, a female cub that lived at the London Zoo from 1915 until her death in 1934. A cub, who in the spring of 1950 was caught in the Capitan Gap Fire, was made into the living representative of Smokey Bear, the mascot of the United States Forest Service. Terrible Ted was a de-toothed and de-clawed bear who was forced to perform as a pro wrestler and whose "career" lasted from the 1950s to the 1970s. Clark's Bears, previously named Clark's Trading Post, is a visitor attraction in Lincoln, New Hampshire known for its trained bear shows since 1949. The American black bear is the mascot of the University of Maine and Baylor University, the latter of which houses two live bears on campus.
=== Ports === The state has 46 public ports and landing stages, four of which fulfill international transit functions: Kiel, Lübeck / Travemünde and Puttgarden on the Baltic Sea, Brunsbüttel on the North Sea. Kiel and Lübeck are also important for freight traffic to Scandinavia and Eastern Europe. Lübeck-Travemünde and Kiel are also important ferry and cruise ports. Puttgarden is the German port of the Vogelfluglinie to Denmark. Brunsbüttel is a significant port for bulk goods and also serves as a foundation for the offshore wind energy industry.
"David J. Gross, a celebrated U.S. theoretical physicist, calls himself an optimist—especially concerning the future of his field. He's certain that somewhere out there lurks a final, unified theory of nature, just waiting to be discovered. But ... he estimates it's more likely that we'll destroy ourselves in nuclear warfare first. And [as a Nobel laureate in physics and] as the latest recipient of a $3-million Special Breakthrough Prize in Fundamental Physics, he's using the opportunity to warn the world of this dire peril. [p. 90.] [Says Gross:] 'I'd estimate that the annual chance for nuclear war is now 2 percent.'" (p. 93.) Jerry Brown, 'I Taste Ashes in the Wind' (review of Serhii Plokhy, The Nuclear Age: An Epic Race for Arms, Power, and Survival, Norton, 422 pp.; David Holloway, Nuclear Weapons: An International History, Yale University Press, 708 pp.; Daniel Ellsberg, edited by Michael Ellsberg and Jan R. Thomas, Truth and Consequence: Reflections on Catastrophe, Civil Resistance, and Hope, Bloomsbury, 363 pp.), The New York Review of Books, vol. LXIX, no. 15 (8 October 2026), pp. 18, 20–21. Reviewer Jerry Brown writes: "Congress is now considering Trump's Golden Dome, a trillion-dollar scheme to place an ineffective missile defense 'shield' over the entire [United States]. ... Our leaders are complacent or distracted with respect to the risks of nuclear horror. They are men driven by grievance and whim. The public is uninformed or else desensitized. ...
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.